COVITREM-1 - Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

Head :
GIBOT Sébastien

Last update : 05/06/2021 | Version : 1 | ID : 73586

print
Print
xml
XML

Export to XML

Please choose the format :

pdf
PDF
xml
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

Which version do you want to export ?

send
Send
General
Identification
Detailed name Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19
Sign or acronym COVITREM-1
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation NCT04544891
General Aspects
Medical area Anesthesiology – Intensive care
Infectious diseases
Study in connection with Covid-19 Yes
Pathology (details) patients hospitalised due to Covid-19
Keywords biomarker, COVID-19
Scientific investigator(s) (Contact)
Name of the director GIBOT
Surname Sébastien
Email s.gibot@chru-nancy.fr
Organization Nancy Regional University Hospital
Collaborations
Participation in projects, networks and consortia Yes
Funding
Funding status Public
Details BPI France
Governance of the database
Sponsor(s) or organisation(s) responsible Nancy Regional University Hospital
Organisation status Public
Presence of scientific or steering committees Yes
Additional contact
Main features
Type of database
Type of database Study databases
Study databases (details) Cohort study
Database recruitment is carried out by an intermediary A selection of health institutions and services
Database recruitment is is made on the basis of: Another treatment or procedure
Database recruitment is carried out as part of an interventional study No
Database objective
Main objective Evaluate the prognostic value of initial TREM-1 activation (first measurement collected) on clinical deterioration in patients hospitalised due to COVID-19 in medical, emergency and intensive care departments
Inclusion criteria Patients aged over 18 years
Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be "probable" or "confirmed" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes).
Registered with a social security scheme or a beneficiary of such a scheme
The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP)
Population type
Age Adolescence (13 to 18 years)
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)
Population covered Sick population
Pathology J96 - Respiratory failure, not elsewhere classified
Gender Male
Woman
Geography area National
Data collection
Dates
Date of first collection (YYYY or MM/YYYY) 2020
Size of the database
Size of the database (number of individuals) [1000-10 000[ individuals
Details of the number of individuals 1009
Data
Database activity Current data collection
Type of data collected Clinical data
Biological data
Clinical data (detail) Direct physical measures
Presence of a biobank Yes
Contents of biobank Serum
Plasma
DNAc/RNAm
Health parameters studied Health event/morbidity
Health event/mortality
Procedures
Participant monitoring Yes
Monitoring procedures Monitoring by contact with the participant (mail, e-mail, telephone etc.)
Links to administrative sources No
Promotion and access
Promotion
Access

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05